Appointed
John Dal Poggetto
Controller
SNOA ·
Sonoma Pharmaceuticals, Inc.
Effective July 17, 2023, our Board of Directors appointed John Dal Poggetto as our Controller.
Ready 8-Ks
50
Latest filing
August 19, 2026, 5:27 PM ET
Top materiality
0.75
Event mix
other_material ×30 · other ×11 · leadership ×7
Sentiment
7 pos · 4 neg · 39 neu
Executive change
recent →
Recent 8-K filings for SNOA
Highest-materiality recent filing
Sonoma Pharmaceuticals enters manufacturing supply agreement with Kenvue for Microcyn products in US
- Agreement with Kenvue Brands LLC for US sale of Microcyn-based products, effective Oct 24, 2025 through March 2027.
- Term includes two optional one-year renewals upon mutual written agreement.
-
Sonoma Pharmaceuticals prices $4.0M public offering of units at $1.35/unit
Offering of 2,962,962 units initially, each unit one share (or pre-funded warrant) and one warrant at $1.35 per unit.
-
Sonoma Pharmaceuticals enters manufacturing supply agreement with Kenvue for Microcyn products in US
Agreement with Kenvue Brands LLC for US sale of Microcyn-based products, effective Oct 24, 2025 through March 2027.
-
Sonoma Pharma terminates EVP/COO Bruce Thornton for cause, effective Oct 18
Bruce Thornton terminated as EVP and Chief Operating Officer on October 18, 2025.
-
Sonoma inks exclusive US distribution deal with WellSpring for Microcyn products
Exclusive US distribution agreement with WellSpring Pharmaceutical, effective Jan 29, 2025.
-
Sonoma Pharmaceuticals terminates exclusive supply agreement with EMC Pharma
EMC Pharma failed to meet minimum purchase quantities; 30-day cure period expired.
-
Sonoma expands Medline distribution to Canada and OTC retail in US and Canada
Amendment No. 1 to Distribution Agreement with Medline dated Oct 17, 2024 adds Canada and OTC wound care sales to retailers.
-
Authorized shares increased from 24M to 50M; reverse split ratio 1:20 effective Aug 29, 2024 at 5pm EDT.
-
Sonoma Pharmaceuticals enters 5-year distribution agreement with Medline for wound care products
Distribution agreement effective August 19, 2024, covers wound cleansers and other products in the United States.
-
Sonoma Pharma receives Nasdaq delisting notice for bid price non-compliance; say-on-pay vote fails
Received Nasdaq notice on Sept 22, 2023 for failure to maintain $1 minimum bid price for 30 consecutive days.
-
Sonoma enters exclusive South Korea distribution deal with Daewoong for Primocyn
Exclusive distribution agreement effective Jan 26, 2023 for Primocyn Skin Solution (Microcyn technology) in South Korea.
-
CEO Amy Trombly appointed to board effective July 22, 2022; amended employment agreement with severance of one-time base salary.
Executive changes
Departed
Chad White
Chief Financial Officer
SNOA ·
Sonoma Pharmaceuticals, Inc.
Effective April 7, 2023, Chad White resigned as our Chief Financial Officer, and our Board of Directors appointed Jerry Dvonch as our interim Chief Financial Officer.
Appointed
(interim)
Jerry Dvonch
interim Chief Financial Officer
SNOA ·
Sonoma Pharmaceuticals, Inc.
Effective April 7, 2023, Chad White resigned as our Chief Financial Officer, and our Board of Directors appointed Jerry Dvonch as our interim Chief Financial Officer.
Appointed
(interim)
Chad White
Chief Financial Officer
SNOA ·
Sonoma Pharmaceuticals, Inc.
Effective on October 3, 2022, our Board of Directors appointed Chad White as our interim Chief Financial Officer.
Departed
Jerry Dvonch
Chief Financial Officer
SNOA ·
Sonoma Pharmaceuticals, Inc.
We accepted the resignation of Mr. Dvonch as Chief Financial Officer effective November 18, 2022.
Role change
Chad White
Chief Financial Officer
SNOA ·
Sonoma Pharmaceuticals, Inc.
Effective November 18, 2022, Mr. White will serve as Chief Financial Officer of the Company.
Departed
Jerry Dvonch
Chief Financial Officer
SNOA ·
Sonoma Pharmaceuticals, Inc.
In connection with the Woodstock office closure, Mr. Jerry Dvonch resigned as our Chief Financial Officer.
Appointed
Amy Trombly
Director
SNOA ·
Sonoma Pharmaceuticals, Inc.
Effective July 22, 2022, the Company’s Board of Directors appointed Amy Trombly, our Chief Executive Officer, to serve as a member of our Board of Directors.
Departed
Sharon Barbari
Director
SNOA ·
Sonoma Pharmaceuticals, Inc.
On July 27, 2021, Sharon Barbari, our director, chair of the audit committee and member of the compensation and nominating and corporate governance committee notified us that she does not intend to stand for re-election at out upcoming annual meeting of stockholders on September 15, 2021 due to personal reasons.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.35 · Most common event other_material